Boehringer-Ingelheim Now RE-LYing On Pradaxa Approval In Stroke Prevention

As Boehringer-Ingelheim scrambles to file its oral anticoagulant Pradaxa with FDA, likely for stroke prevention in patients with atrial fibrillation, physicians already have started weighing the pros and cons of the drug's two possible doses

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet